Mobile Trading

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE749.05-14.45 (-1.89 %)
PREV CLOSE ( ) 763.50
OPEN PRICE ( ) 755.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3445
TODAY'S LOW / HIGH ( )725.35 765.00
52 WK LOW / HIGH ( )272.2 808.5
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)33.9021.3119.8730.4750.04
   CEPS(Rs)50.7441.1044.0455.5578.63
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)419.65364.74344.38329.50313.18
   Tax Rate(%)36.9136.1829.96-11.85-27.21
Margin Ratios
   Core EBITDA Margin(%)9.819.9110.8110.359.81
   EBIT Margin(%)11.107.446.856.1511.23
   Pre Tax Margin(%)11.097.426.836.078.86
   PAT Margin (%)6.994.744.786.7911.27
   Cash Profit Margin (%)10.479.1310.6012.3717.70
Performance Ratios
   ROA(%)6.754.644.507.1810.30
   ROE(%)8.646.015.909.8517.40
   ROCE(%)13.178.677.727.8912.37
   Asset Turnover(x)0.970.980.941.060.91
   Sales/Fixed Asset(x)1.030.980.910.980.88
   Working Capital/Sales(x)2.052.152.313.244.01
Efficiency Ratios
   Fixed Capital/Sales(x)0.971.021.091.021.13
   Receivable days54.2847.6937.8721.4820.89
   Inventory Days62.5973.3280.6874.6986.94
   Payable days69.9153.5255.6957.3157.86
Valuation Parameters
   PER(x)8.8415.318.158.825.49
   PCE(x)5.907.943.684.843.49
   Price/Book(x)0.710.890.470.820.88
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.500.680.370.590.65
   EV/Core EBITDA(x)3.815.752.905.004.89
   EV/EBIT(x)4.489.155.379.545.83
   EV/CE(x)0.570.770.410.610.65
   M Cap / Sales0.620.730.390.600.62
Growth Ratio
   Net Sales Growth(%)7.728.27-7.449.5061.53
   Core EBITDA Growth(%)18.691.19-0.11-4.0759.14
   EBIT Growth(%)60.7017.583.14-40.091061.31
   PAT Growth(%)59.057.25-34.77-34.07717.70
   EPS Growth(%)59.057.25-34.77-39.12717.70
Financial Stability Ratios
   Total Debt/Equity(x)0.000.080.090.100.13
   Current Ratio(x)3.314.533.913.002.40
   Quick Ratio(x)2.582.992.461.641.17
   Interest Cover(x)1099.26477.45322.4476.694.73
   Total Debt/Mcap(x)0.000.090.200.120.15

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by  Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.